



COVID-19

Questions, Answers and Actions

Anticoagulation in cancer

Question: "Can patients with active cancer currently prescribed low molecular weight heparin (LMWH) for the **treatment** of a deep vein thrombosis (DVT) or pulmonary embolism (PE) be switched to a direct-acting oral anticoagulant (DOAC)?"

Answer: Certain DOACs can be considered for patients with active cancer and a confirmed proximal DVT or PE, however they are not specifically licensed in patients with active cancer.¹

Note dabigatran is **not** suitable as it is contraindicated in patients with cancer.²

Particular patient groups would **not** be suitable to be switched to a DOAC and should remain on LMWH. These are listed below,

- Patients with cancers that have a high risk of bleeding, for example, gastrointestinal or genitourinary cancers.²⁻³
- Patients who have had a DVT or PE whilst already anticoagulated.
- For patients who have a variable dietary intake rivaroxaban may not be suitable for as it must be taken with food.⁴ There have been reports of a lack of efficacy in patients who have taken it on an empty stomach.⁵ Apixaban and edoxaban are not required to be taken with food.⁶⁻⁷

Action: Suitable patients may be switched to; apixaban, edoxaban or rivaroxaban noting that prescribing will be outside of the product license. Whilst usually advised to be that of the lowest acquisition cost where more than one product is available for the indication, choice of DOAC should take place across all three to ensure continuity of supply during the current pandemic. Prescribers will take full responsibility for prescribing and patients should also be made aware of this and their consent documented.¹

DOACs are more likely to have drug interactions with other medicines than LMWH. Prescribers should consider patient's other medicines which may have been prescribed in either primary or secondary care - see the [BNF](#) interactions checker. Additionally, prescribers should also assess the effect that systemic anticancer therapies may have on a patient's renal and hepatic function and if a DOAC is still appropriate.

Switching treatment from LMWH to a DOAC can be done at the next scheduled dose. DOACs and LMWH should not be administered simultaneously.⁴⁻⁶ See individual SmPC for dosing information.

Patients receiving LMWH as **prophylaxis** of DVT or PE as they are prescribed thalidomide, pomalidomide or lenalidomide with steroids could alternatively be prescribed aspirin 75 or 150mg.⁸

References

1. NICE NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020. Available at www.nice.org.uk/guidance/ng158.
2. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Available at <https://bnf.nice.org.uk>
3. Key N et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 2020, 38:5, 496-520
4. SPC. Xarelto 20mg film-coated tablets. November 2019. Available at <https://www.medicines.org.uk/emc/product/2793>

5. MHRA. Drug Safety Update volume 12, issue 12: July 2019: 3. Available at <https://www.gov.uk/drug-safety-update/rivaroxaban-xarelto-reminder-that-15-mg-and-20-mg-tablets-should-be-taken-with-food>
6. SPC. Eliquis 5mg film-coated tablets. April 2020. Available at <https://www.medicines.org.uk/emc/product/2878>
7. SPC. Lixiana 60mg film-coated tablets. July 2019. Available at <https://www.medicines.org.uk/emc/product/6905>
8. NICE NG89. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. August 2019. Available at <https://www.nice.org.uk/guidance/ng89>

Version: 2.0

Changes to this version:

Removed link to NHSE speciality guide as no longer available

Date prepared: 21st April 2020, updated 30th September 2020

Prepared by: Daniel Hill. Regional Drug and Therapeutics Centre.

Review date: Ongoing

Regional Drug and Therapeutics Centre
16/17 Framlington Place, Newcastle upon Tyne, NE2 4AB

Tel: 0191 213 7855 Fax: 0191 261 8839
E-mail: rdtc.rxsupp@nuth.nhs.uk Website: www.rdtc.nhs.uk



[@RDTC_Rx](https://twitter.com/RDTC_Rx)